Semaphorin 4B is an ADAM17-cleaved adipokine that inhibits adipocyte differentiation and thermogenesis

Abdulbasit Amin, Marina Badenes, Johanna Tüshaus, Érika de Carvalho, Emma Burbridge, Pedro Faísca, Květa Trávníčková, André Barros, Stefania Carobbio, Pedro M. Domingos, Antonio Vidal-Puig, Luís F. Moita, Sarah Maguire, Kvido Stříšovský, Francisco J. Ortega, José Manuel Fernández-Real, Stefan F. Lichtenthaler, Colin Adrain

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Objective: The metalloprotease ADAM17 (also called TACE) plays fundamental roles in homeostasis by shedding key signaling molecules from the cell surface. Although its importance for the immune system and epithelial tissues is well-documented, little is known about the role of ADAM17 in metabolic homeostasis. The purpose of this study was to determine the impact of ADAM17 expression, specifically in adipose tissues, on metabolic homeostasis. Methods: We used histopathology, molecular, proteomic, transcriptomic, in vivo integrative physiological and ex vivo biochemical approaches to determine the impact of adipose tissue-specific deletion of ADAM17 upon adipocyte and whole organism metabolic physiology. Results: ADAM17adipoq-creΔ/Δ mice exhibited a hypermetabolic phenotype characterized by elevated energy consumption and increased levels of adipocyte thermogenic gene expression. On a high fat diet, these mice were more thermogenic, while exhibiting elevated expression levels of genes associated with lipid oxidation and lipolysis. This hypermetabolic phenotype protected mutant mice from obesogenic challenge, limiting weight gain, hepatosteatosis and insulin resistance. Activation of beta-adrenoceptors by the neurotransmitter norepinephrine, a key regulator of adipocyte physiology, triggered the shedding of ADAM17 substrates, and regulated ADAM17 expression at the mRNA and protein levels, hence identifying a functional connection between thermogenic licensing and the regulation of ADAM17. Proteomic studies identified Semaphorin 4B (SEMA4B), as a novel ADAM17-shed adipokine, whose expression is regulated by physiological thermogenic cues, that acts to inhibit adipocyte differentiation and dampen thermogenic responses in adipocytes. Transcriptomic data showed that cleaved SEMA4B acts in an autocrine manner in brown adipocytes to repress the expression of genes involved in adipogenesis, thermogenesis, and lipid uptake, storage and catabolism. Conclusions: Our findings identify a novel ADAM17-dependent axis, regulated by beta-adrenoceptors and mediated by the ADAM17-cleaved form of SEMA4B, that modulates energy balance in adipocytes by inhibiting adipocyte differentiation, thermogenesis and lipid catabolism.

Original languageEnglish
Article number101731
JournalMolecular Metabolism
Volume73
DOIs
StatePublished - Jul 2023
Externally publishedYes

Keywords

  • ADAM17/TACE
  • Adipose tissue
  • Beta-adrenoceptor signalling
  • Cold challenge
  • Metabolism
  • Obesity
  • Semaphorin4B Sema4b
  • Thermogenesis

Fingerprint

Dive into the research topics of 'Semaphorin 4B is an ADAM17-cleaved adipokine that inhibits adipocyte differentiation and thermogenesis'. Together they form a unique fingerprint.

Cite this